Serum hepatic biomarkers in women with obstetric cholestasis and a concurrent <scp>SARS‐CoV</scp>‐2 infection

D’Ambrosi, Francesco; Maso, Matteo Di; Viscardi, Anna; Ossola, Manuela Wally; Soldavini, Chiara Maria; Cetera, Giulia Emily; Erra, Roberta; Ferrazzi, E.

doi:10.1111/jog.15383

Cited by 2 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to its effect on the liver, COVID-19 is associated with higher aminotransferase levels, especially in pregnant patients with IHC[ 54 ]. Increased levels of serum BA are the most sensitive diagnostic marker of IHC, likely due in part to its impaired resorption as a result of increased estrogen.…”

Section: Liver Injuries In Pregnant Covid-19 Patientsmentioning

confidence: 99%

“…We reviewed available literature regarding COVID-19 in women with pregnancy-related hepatic injury. In total, 34 pregnant COVID-19 patients and 37 infants were included in our review[ 49 , 50 , 54 , 56 , 60 - 62 , 65 , 68 ]. We determined that the most common reported liver disease in pregnancy was IHC, followed by HELLP syndrome, and AFLP (61.7%, 32.3% and 2.9%, respectively).…”

Section: Pregnancy Outcomes After Liver Injurymentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 related liver injuries in pregnancy

Sekulovski¹,

Bogdanova-Petrova²,

Peshevska-Sekulovska³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

While severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly spread across the globe, our understanding of its pathogenic mechanisms evolved. Importantly, coronavirus disease 2019 (COVID-19) is now considered a syndromic multisystem inflammatory disease involving not only the respiratory system but also the cardiovascular, excretory, nervous, musculoskeletal, and gastrointestinal systems. Moreover, a membrane-bound form of angiotensin-converting enzyme 2, the entry receptor for SARS-CoV-2, is expressed on the surface of cholangiocytes and hepatocytes, suggesting the potential of COVID-19 to involve the liver. With the widespread distribution of SARS-CoV-2 throughout the population, infection during pregnancy is no longer a rare occurrence; however, little is known about the course of hepatic injuries and related outcomes in pregnant SARS-CoV-2-positive women. Thus, the understudied topic of COVID-related liver disease during pregnancy poses a great challenge for the consulting gynecologist and hepatologist. In this review, we aim to describe and summarize potential liver injuries in pregnant women with COVID-19.

show abstract

Section: Liver Injuries In Pregnant Covid-19 Patientsmentioning

confidence: 99%

Section: Pregnancy Outcomes After Liver Injurymentioning

confidence: 99%

COVID-19 related liver injuries in pregnancy

Sekulovski¹,

Bogdanova-Petrova²,

Peshevska-Sekulovska³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…COVID-19 disease is associated with hepatic involvement not only during the initial infection but also as sequelae [14][15][16]. Regarding pregnancy, elevated liver enzymes have been reported in patients with COVID infection and intrahepatic cholestasis of pregnancy (ICP) compared to non-infected women [17]. As some authors have hypothesized a possible correlationcausation sequence between maternal COVID-19 and ICP [18], the objective of this study was to assess the incidence and course of ICP before and during the pandemic era.…”

Section: Introductionmentioning

confidence: 99%

Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic

Malarkiewicz,

Nowacka,

Januszaniec

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Intrahepatic cholestasis of pregnancy (ICP) stands as one of the most prevalent concerns in maternal–fetal medicine, presenting a significant risk to fetal health and often associated with liver dysfunction. Concurrently, the coronavirus-19 (COVID-19) infection can lead to hepatic cell injury through both direct and indirect pathways. Hypothetically, these two conditions may coincide, influencing each other. This study aimed to comparatively assess the incidence and severity of ICP before and during the COVID-19 pandemic. Methods: A retrospective cohort study was conducted, comparing the incidence and severity of ICP between January 2018 and February 2020 (pre-COVID-19 period) and March 2020 to March 2022 (COVID-19 period) across two hospitals, encompassing 7799 deliveries. The diagnosis of ICP was established using the ICD-10 code and defined as total bile acids (BA) levels ≥ 10 μmol/L. Statistical analysis included descriptive statistics, Chi-square and Mann–Whitney U tests, as well as multiple or logistic regression analysis. Results: A total of 226 cases of ICP were identified. The incidence of mild cholestasis (BA < 40 μmol/L) was lower during the pandemic compared to before (3% before versus 2%, p < 0.05), while the incidence of moderate and severe ICP remained unchanged (0.6% before vs. 0.4%, p = 0.2). Overall, the total incidence of ICP was lower during the pandemic (3.6% before versus 2.4%, p = 0.01). No significant differences were observed in severity (as defined by BA and liver function test levels), rates of caesarean section, or neonatal birth weights. Conclusions: During the COVID-19 pandemic, the total incidence of ICP appeared to be lower. However, this reduction was primarily observed in cases of mild ICP, potentially indicating challenges in detection or reduced access to medical services during this period. The incidence of moderate and severe ICP remained unchanged, suggesting that these forms of the condition were unaffected by the pandemic’s circumstances.

show abstract

Serum hepatic biomarkers in women with obstetric cholestasis and a concurrent SARS‐CoV‐2 infection

Cited by 2 publications

References 39 publications

COVID-19 related liver injuries in pregnancy

COVID-19 related liver injuries in pregnancy

Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic

Contact Info

Product

Resources

About